Alex Matter,
CEO,
Agency of Science Technology & Research
Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore.
Previously, he was Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation.
Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec® and more recently, Tasigna®, building and leading the teams that discovered these and several other anticancer drugs.
|
|
|
Add to Calendar ▼2014-09-11 00:00:002014-09-12 00:00:00Europe/LondonEnabling Genomic Technologies and Screening Asia 2014Enabling Genomic Technologies and Screening Asia 2014 in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
